Key result
High-dose antithrombin III blunts white blood cell and platelet activation during simulated cardiopulmonary bypass.
Why the study?
Does antithrombin III supplementation reduce white blood cell and platelet activation during simulated cardiopulmonary bypass?
Does antithrombin III supplementation reduce white blood cell and platelet activation during simulated cardiopulmonary bypass?
High-dose antithrombin III demonstrates direct anti-inflammatory and anti-platelet effects during simulated cardiopulmonary bypass, suggesting potential clinical relevance for mitigating CPB complications.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for antithrombin III in CPB; should not yet change clinical practice.
Rinder et al. (2006) studied simulated cardiopulmonary bypass. Antithrombin III vs. controls (minimally heparinized blood) was evaluated on white blood cell activation (CD11b up regulation or elastase release), platelet activation and fibrin generation. High-dose antithrombin III significantly blunted monocyte and neutrophil CD11b up regulation, neutrophil elastase release, and platelet activation during simulated cardiopulmonary bypass.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: